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Traditionally, the four dengue virus serotypes have been associated with fever, rash, and the more severe forms, haemorrhagic fever
and shock syndrome. As our knowledge as well as understanding of these viruses increases, we now recognise not only that they
are causing increasing numbers of human infections but also that they may cause neurological and other clinical complications,
with sequelae or fatal consequences. In this review we attempt to highlight some of these features in the context of dengue virus
pathogenesis. We also examine some of the efforts currently underway to control this “scourge” of the tropical and subtropical
world.
1. Introduction
Dengue fever is a mosquito-borne virus disease of humans.
In terms of numbers of individuals infected, it is by far the
most devastating of all the recognised arthropod-transmitted
virus diseases. It is estimated that more than 3 billion humans
live in dengue endemic regions of the world, and currently,
more than 50 million infections occur annually with at
least 500,000 individuals requiring hospitalisation [1]. Of
these, tens of thousands have a high risk of developing
haemorrhagic disease, potentially with fatal consequences
depending to a large extent on the quality of the available
medical services.
The dengue viruses are positive stranded RNA viruses in
the genus Flavivirus, family Flaviviridae [2]. There are four
distinct dengue virus (DENV) serotypes that share antigenic
relationships (DENV-1, DENV-2, DENV-3, and DENV-4),
and although infection with one serotype confers lifelong
protection against that serotype, it does not necessarily
protect against a secondary infection with a heterologous
serotype. Indeed, nonprotective but cross-reactive antibodies
may enhance disease severity [3]. Currently, there are no
effective vaccines or antiviral drugs against these viruses.This
problem is being addressed as a matter of urgency as failure
to develop effective DENV control strategies will inevitably
result in a further increase in the number of infected humans,
as predicted more than a decade ago [4].This problem is also
exacerbated by the continuing dispersal of these viruses to
new geographic regions.
This review therefore focuses on our current understand-
ing of dengue virus pathology, epidemiology, pathogenesis,
evolution, biogeography, and disease control.
2. Dengue Fever/Haemorrhagic
Fever/Shock Syndrome
2.1. Clinical Picture. Inmost cases asymptomatic or relatively
mild disease follows infection with dengue virus. However, to
take into account the increasing number of clinical cases, the
World Health Organization (WHO) produced guidelines [5]
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in which they identified the clinical pictures resulting from
infection with dengue virus. The first, known as dengue
fever (DF), is characterised by an abrupt onset of fever
accompanied by frontal headache and retroorbital pain,
followed by a variety of possible clinical symptoms such as
myalgia, arthralgia, vomiting, and weakness. A generalised
maculopapular rash appears one or two days after fever
defervescence. Minor haemorrhagic manifestations such as
petechiae may be observed in some patients. DF is generally
self-limiting and rarely fatal. Most patients recover without
complications around ten days after the onset of illness.
The second clinical picture, dengue haemorrhagic fever
(DHF), is a more severe form of the disease and occurs in
up to 5% of dengue cases. It is initially characterized by the
same variety of clinical symptoms as are seen in DF. The
critical period in DHF starts at the moment of defervescence
but haemorrhagic manifestations may occur 24 hours earlier.
A positive tourniquet test indicates that the patient has
increased capillary fragility. Petechiae, bleeding at venepunc-
ture sites, epistaxis, gum bleeding, and haematemesis may
also be observed. High fever, haemorrhagic manifestations,
thrombocytopenia (platelet count 100 000/mm3 or less), and
haemoconcentration (>20% difference) characterize DHF.
Plasma leakage is the most significant pathophysiological
event in determining the severity of the disease. Signs of
circulatory failure such as irritability, cold clammy extrem-
ities, flushed face, and restlessness may be observed. This
crisis usually persists for 24–36 hours. With appropriate
supportive medicine and carefully monitored intravenous
isotonic crystalloid therapy, to ensure adequate fluid replace-
ment, most patients recover. However, during this critical
period, it is essential to look for characteristic warning signs
of worse to come. Patients progressing to shock (dengue
shock syndrome—DSS) show intense abdominal pain or
tenderness, persistent vomiting, weak pulse, and hypoten-
sion. If increased vascular permeability progresses to vascular
collapse the outcome is usually fatal as a result of irreversible
DSS. In addition to DF, DHF, and DSS, it is now recog-
nised that other clinical manifestations can be associated
with infection by dengue virus, for example, encephalitis,
myocarditis, hepatitis, cholecystitis, myelitis, and acute colitis
[6–11].
Despite the rigour of the DF/DHF/DSS classification and
its intrinsic worth in clinical case management, in recent
years, a growing number of clinicians and authors have
argued that the 1997WHO scheme for dengue clinical classi-
fication should be reassessed [12–14] because it distinguishes
strictly between DF, DHF, and DSS, whereas it is now recog-
nised that the point of transition between DF and DHF is not
easily defined. The requirements for the WHO definition of
DHF (fever, haemorrhage, thrombocytopenia, and signs of
plasma leakage) are not always satisfied; severe thrombocy-
topenia may be observed in uncomplicated as well as severe
cases associated with “unusual manifestations” and therefore
may not be consistent with theDHF/DSS classification [15]. A
WHO/TDR-supported prospective clinical multicentre study
across dengue-endemic regions was established to collect
and coordinate specific criteria for classifying clinical cases
into levels of severity [16]. The study confirmed that, by
using a set of clinical and/or laboratory parameters, one sees
a clear-cut difference between patients with severe dengue
fever and those with nonsevere dengue fever. However, for
practical reasons it was considered necessary to split the
large group of patients with nonsevere dengue into two
subgroups: patients with warning signs (abdominal pain or
tenderness, persistent vomiting, clinical fluid accumulation,
mucosal bleeding, lethargy, restlessness, liver enlargement
>2 cm, and increase in hematocrit concurrent with rapid
decrease in platelet count) and those without these warning
signs. On the other hand, the criteria for severe dengue fever
include extensive plasma leakage, severe bleeding, or severe
organ impairment.
The third and most recent edition of the WHO/TDR
dengue guidelines for diagnosis, treatment, prevention, and
control includes a new clinical classification [17]. This publi-
cation serves as an authoritative reference source for health
workers and researchers. These new guidelines provide a
revised case classification which is intended to facilitate
effective triage and patient management and collection of
improved comparative surveillance data [18]. However, due
to the recommendation that cases of dengue fever with
warning signs and also cases of severe dengue fever should
be admitted to hospital, there is concern that this could result
in overadmission of patients to hospitals during epidemics,
inevitably reducing the efficiency of patient triage and
adversely affecting the quality of clinical case management
[19, 20]. Furthermore there is additional concern that the
WHO/TDRclassificationmay impact significantly on dengue
pathogenesis research since it requires the identification
and study of distinct dengue syndromes. Because the 2009
WHO case definitions do not require laboratory tests for the
diagnosis of severe dengue, it is considered that retrospective
identification of patients with clinically significant vascular
permeability, from data on hospital charts, may be difficult
if not impossible [21]. The previous discussion highlights
the difficulties of designing a totally acceptable classification
scheme for dengue pathogenesis.
2.2. History of DF and DHF. Clinically diagnosed DF was
widespread during the 18th and 19th centuries in North
and South America, the Caribbean Basin, Asia, and Aus-
tralia. In the Americas, this was largely due to the repeated
introduction from Africa of Stegomyia (St.) aegypti (formerly
Aedes aegypti) [22–24]. Moreover, together with yellow fever
virus (YFV), DENV-infected humans and mosquitoes were
introduced via the slave ships and other commercial vessels
that crossed the Atlantic Ocean from Africa during the past
five or more centuries [25–31].
It is also important to note that disease clinically com-
patible with the more severe and often fatal syndromes, DHF
and DSS, was sporadically reported from 1780 onwards [32]
although it is not clear if the more severe cases were confined
to individuals of European descent.
DF thus became endemic in Latin America and the
Caribbean region, periodically causing epidemics. At the
same time, YFV was also causing epidemics in South
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America, prompting the Pan American Health Organisation
(PAHO) to introduce a mosquito-eradication programme
which lasted from 1946 until the late 1970s. Since both DENV
and YFV are transmitted to humans via St. aegypti this erad-
ication campaign in South America also resulted in a lower
incidence of DF in South America. Thus, DF was confined
mainly to the Caribbean basin [33, 34]. Subsequently, the
gradual decline of mosquito control measures and increasing
introduction and dispersal of mosquitoes via transportation
for commercial andmilitary purposes led to the reemergence
of dengue as a major health problem during the mid and
later parts of the 20th Century.The incidence of dengue fever
increased dramatically in Southeast Asia duringWorldWar II
and continued to intensify with increased geographic spread
of the viruses and the principal mosquito vector, St. aegypti.
In addition to the major influence of increased shipping and
air-traffic globally, other major factors for the reemergence of
dengue fever include ecological and demographic changes in
the tropical zones [2, 34–39].
During the 1980s and 1990s, rapidly expanding popula-
tions of St. aegypti in Brazil resulted in successive epidemics
due toDENV-1, DENV-2, andDENV-3. In Brazil, these infec-
tions presented mostly as DF, with surprisingly few cases of
DHF. This contrasts with Asia where the proportion of DHF
cases was significantly higher during DF epidemics. These
differences have been partly attributed to the widespread
presence of dengue virus resistance genes in Latin Americans
with African ancestry [33, 40, 41]. The differences may also
be partly explained by the high levels of antibody against the
American DENV-2 genotype and antigenically cross-reactive
DENV-1, both of which had been endemic in Latin America
for many years.
Today, all four DENV serotypes circulate in Africa, South
and Southeast Asia, theWestern Pacific region, theCaribbean
basin, and Central and South America [39, 42–44]. Frequent
introductions into the Southern states of North America
are also regularly recorded although to date they have not
resulted in epidemic outbreaks in the USA; DF has the
potential to become reestablished as an endemic disease in
this country. In fact, sustained transmission of dengue has
occurred in Florida during recent years. Conditions exist
that could facilitate sustained dengue transmission, including
environmental factors, competent mosquito vectors, limited
vector and dengue surveillance, increased domestic outdoor
daytime activities in warmer months, and low public aware-
ness of the disease [45]. Indeed, dengue continues to spread
more widely as demonstrated in 2010 by the first recorded
cases of autochthonous dengue fever in southern France [46]
and Croatia [47].
Many countries in the tropics and subtropical regions
show cocirculation of at least two DENV serotypes [36], and
increasingly, cocirculation of all 4 serotypes is being recorded
in individual countries. Taken together with the ecological
and demographic changes, this partly explains why the
pattern of epidemics is gradually increasing from a frequency
of outbreaks every 3–5 years to approximately every 2 years
[48]. Additional explanations for this increased incidence
include the possibility that more highly pathogenic strains
of DENV are also emerging [44, 49–51]. Greater awareness
of this disease, as the result of more extensive monitoring,
is also impacting on our understanding of and the apparent
increased periodicity of dengue virus epidemiology.
Comparison of disease incidence in Asia and Latin
America reveals a distinct difference in the age distribution
of DF and DHF. In Asia, hospitalizations principally involve
children, whereas in the Americas, they tend to involve a
greater proportion of adults [33]. The reasons for this appar-
ent difference have not been adequately defined. However, to
complicate this issue, a recent epidemic in the State of Rio
de Janeiro revealed that the incidence of DHF in children
was significantly higher than in previous epidemics in Brazil
[52, 53].
2.3. Risk Factors Associated with the Development of Severe
Dengue. The principal vector associated with all 4 DENV
serotypes is the African mosquito St. aegypti an urban-
dwelling anthropophilic mosquito. However, St. albopicta the
Asian “Tiger” mosquito is also competent to reproduce and
transmitDENVbetween humans. In contrast with St. aegypti,
St. albopicta is peridomestic, with a preference for the rural
environment. In some parts of Asia and Africa, St. albopicta
has displaced St. aegypti [54, 55]. A possible scenario of this
changing pattern ofmosquito distribution and the continuing
dispersal of St. albopicta is that the dengue viruses will
disperse even more widely, gradually establishing in the
warmer regions of the temperate zones, including Europe
[46, 47, 56, 57], the southern regions of North America [58],
and more northern regions of Asia [59].
The pathogenetic basis for DHF has been a subject of
study for decades, and whilst significant progress has been
made in understanding the most important risk factors
involved, the precise biochemical and immunological path-
ways have not yet been defined [60–62]. Amongst the several
possibilities that have been identified, there is compelling
evidence that secondary infectionwith a heterologousDENV
serotype, or primary infection in infants born to dengue-
immune mothers, is an important individual risk factor
for DHF/DSS [63–70]. During secondary infection with a
different serotype, the presence of low levels of heterotypic
neutralizing antibodies may reduce disease severity. Alter-
natively, in the absence of such neutralizing antibodies, het-
erotypic cross-reactive antibodies may form complexes with
the virus and the Fc-receptors on these complexed antibodies
may attach to mononuclear phagocytes, thus enhancing the
efficiency of infection and thereby increasing the number of
infectedmononuclear phagocytes [71–74].This phenomenon
is known as antibody dependent enhancement (ADE) [75].
Humans infected with one serotype maintain a life-long pro-
tective immunity to infection by the homologous virus, but
protective immunity to infectionwith heterologous serotypes
is relatively short-lived [76].The precisemechanism bywhich
DENV replication is amplified in the infected cells remains
unclear. One possibility is that there is a relationship between
DENV-ADE infection, suppression of nitric oxide during the
innate immune response, and the corresponding cytokine-
expression pattern in THP-1 cells [77]. Recent evidence
suggests that viral susceptibility or resistance to nitric oxide
may be regulated by the viral NS5 protein [78].
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It has also been argued that strain differences in virulence
may contribute to disease severity [51, 79–84]. However, the
fact that severe dengue disease is identified most consistently
following secondary dengue infections supports the view that
virulence must be defined in a two-infection context [39].
Host risk factors such as gender, ethnicity, the presence of
chronic disease (bronchial asthma, diabetes mellitus, and
sickle cell anaemia) [85–87] and also the genetic character-
istics of the individual are also likely predisposing factors for
severe illness. Human leukocyte antigen (HLA), Fc𝛾R, tumor
necrosis factor- (TNF-) 𝛼, and dendritic cell-specific intra-
cellular adhesion molecule-3-grabbing nonintegrin (DC-
SIGN), among other genes, have been associated with the
pathogenesis of dengue [41, 66, 86, 88–93]. In addition, T-cell
mediated immune mechanisms, involving skewed cytokine
responses resulting in plasma leakage, are also risk factors
for DHF [62]. It has been proposed that an inappropriate
immune response to the secondary virus infection, that in
turn induces reactivation of cross-memory T cells specific
for the first rather than the secondary DENV infection,
results in delayed viral clearance [94, 95]. More recently,
it was suggested that the presence of an effective antiviral
inflammatory response in the presence of adequate immune
regulation could be associated with protection during dengue
secondary infection [96]. However, as highlighted in a recent
review on dengue pathogenesis, it is worth noting that other
infectious diseases and inflammatory disorders result in
elevated cytokines without the attendant increased vascular
permeability seen in severe dengue [97]. Indeed, one of the
major challenges in dengue,magnified due to absence of good
animal models of disease, is to dissect those elements of the
host immune response that are causally linked to capillary
permeability from those that simply reflect the normal host
immune response to a pathogen [97].
Independent of this, antibodies specific for the NS1
viral protein may form immune complexes with the NS1
protein in the circulation and on the surface of infected cells
leading to complement activation [98]. An additional risk
factor for DHF is believed to be dependent on autoimmune
responses against cross-reactive viral components. For exam-
ple, antibodies specific for dengue virus NS1 protein may
induce platelet lysis and/or nitric oxide-mediated apoptosis
of endothelial cells, contributing to thrombocytopenia and
vascular damage [99–104].
The serious complications observed during dengue infec-
tion occur as plasma viremia is resolving. This is thought
to be immunologically mediated. Tam et al. performed a
randomised trial to verify the effects of short-course oral
corticosteroid therapy in early dengue infection. No associ-
ation between treatment allocation and any of the predefined
clinical, hematological, or virological endpoints was found
[105]. Unexpectedly, the steroid doses administered were
not immunosuppressive. Based on these observations it was
suggested that rather than dengue-mediated vascular per-
meability being T-cell mediated, an alternative pathogenetic
mechanism could involve the dengue soluble complement
fixing antigen or the viral NS1 protein. Indeed, it was recently
proposed that during the late stages of clinically apparent
dengue infection, secreted DENV NS1 protein may bind to
prothrombin and inhibit its activation, which in turn could
contribute to the prolongation of activated partial throm-
boplastin time and haemorrhage in DHF patients [106].
Also, previous studies on the virological course of dengue
infections in monkeys have shown that the peak of cellular
infection occurs at the end of the viremic phase. Accordingly,
it was proposed that dengue vascular permeability syndrome
could be the equivalent of a viral toxicosis induced by
circulating NS1 protein [107].
Whilst higher levels of viremia and circulating NS1
protein have been associated with dengue disease severity
[108], collective results arising from different epidemiological
settings are inconclusive, showing variations depending on
the infecting serotype and patient immune status [109–112].
Therefore, the usefulness of these markers for the recognition
of patients with increased risk of progression towards the
more severe forms of dengue is still limited.
2.4. Underlying Basis for the Emergence of DHF in Particular
Epidemiological Settings. Taking into account many of the
factors described earlier and based on observations made
during the 1981 Cuban epidemic of DF/DHF, Kouri and
coworkers presented an integral hypothesis in which the
association of different factors, such as immunological status,
genetic background, host condition, viral strain, and epi-
demiological and ecological conditions, determines whether
or not and to what extent, DHF will be involved in any
particular epidemic [113]. Research conducted during the
past 20 years strongly supports this unifying view of the
situation [3, 39, 48, 114].
With the exception of Chile, Uruguay, and Cuba, that
experience occasional epidemics, resulting from introduced
virus, DF is endemic in Latin America and the Caribbean
region. Cuba is a relatively small island with a well-integrated
medical health and research infrastructure. When combined
with the epidemiological history of DF in Cuba, this situation
has provided a unique opportunity to investigate the specific
risk factors for severe illness in detail [48]. Firstly, it is
important to realise that from the end of World War II
until 1977, dengue virus was not evident in Cuba. This was
supported by a national seroepidemiological survey in 1975,
which identified only 2.6% of the population with DENV
hemagglutination-inhibition (HI) antibodies. Importantly,
most of the positives were individuals older than 45 years
[115, 116]. However, in 1977, based on serological evidence
[117] it was estimated that up to 44.5% of all Cubans
became infected by an introduced Asian strain of DENV-1.
Nevertheless, no cases of DHF were recorded. These results
demonstrate that in the absence of heterologous immunity,
primary DENV-1 infections did not result in cases of DHF
and, bearing in mind that subsequent DHF epidemics in
Cuba all involved secondary infections (see later), the results
strongly support the contention that secondary infections by
heterologous serotypes are a very important risk factor for
DHF as proposed previously [118].
During the past 28 years, three DENV-epidemics involv-
ing DHF have occurred in Cuba. The first epidemic started
in 1981 [113], the second was seen in 1997 [65], and
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the third occurred in 2001 [63]. During each epidemic,
secondary infection was demonstrated as themost important
host risk factor for DHF. Additionally, specific sequential
virus serotypes were associated with severe disease, indepen-
dent of the time-gap between the primary and secondary
infection. For example, in Cuba, two epidemics of DHF have
been associated with primary infections due to an Asian
strain of DENV-1 and secondary infections due to DENV-
2 (i.e., DENV-1/DENV-2) [119, 120]. Significantly, during the
1997 Cuban epidemic, it was demonstrated for the first time
that there was a higher risk of DHF in DENV-1/DENV-2
individuals when the average time gap between primary and
secondary infections was about 20 years as opposed to 4
years, a more commonly reported timespan [64]. Moreover,
comparison of attack rates and case fatality rates, in the same
age groups, revealed that during the 1997 epidemic the rate in
patients older than 15 years of age was 40 times higher than
during the 1981 epidemic [121].
Subsequently, another Cuban epidemic, caused by
DENV-3 and involving cases of DHF, occurred in 2001.Thus,
DHF occurred in DENV-3-infected Cubans 24 years after
primary exposure to DENV-1 infection [122]. Interestingly,
Cubans infected sequentially with DENV-1/DENV-3 were
associated with severe disease whilst those infected
sequentially with DENV-2/DENV-3 were associated with
milder disease or asymptomatic infections [63, 123]. Addi-
tionally, the DENV-3 immune individuals, infected during
the 2001 Cuban epidemic, revealed differences in the neu-
tralization capability of their sera to different DENV-3 strains
belonging to different genotypes [124]. This observation
might be anticipated taking into account that differences
in neutralisation capability have been found using different
genotypes of DENV-2. However, it was highly significant to
find differences in neutralisation against strains belonging
to the same genotype [125]. Moreover, the strains involved
in the Cuban 1981, 1997, and 2001 epidemics [80, 125, 126]
had previously been associated with severe epidemics and
therefore had the potential to produce DHF. Nevertheless,
in all of these epidemics, an extremely high number of
primarily infected individuals were asymptomatic [64].
Using human volunteers, Dr. Albert Sabin was the first
scientist to demonstrate that heterotypic immunity can pre-
vent disease induced by a different dengue virus serotype
[127]. Whilst DENV-1 immunity did not appear to prevent
DENV-2 infections, partial immunity may have downregu-
lated infections, thus reducing severity tomild disease during
secondary dengue infections. It has been postulated that
if virological factors are involved in determining disease
severity, they may reflect common antigenic determinants
shared between the first and second infecting viruses [39]. An
exceptional illustration of this phenomenon is the neutraliza-
tion of American genotype DENV-2 by human antibodies to
DENV-1 [81]. These results suggest that the apparent lower
virulence of American genotype DENV-2 results from a
DENV-1 like surface epitope on the DENV-2 that permits
partial neutralization (and downregulation of disease) by
DENV-1 antibodies [81]. In contrast, Asian genotypesDENV-
2 are poorly neutralised by human antibodies to DENV-
1 [128]. Furthermore, a significant increase in the mean
titre of homologous DENV-1 neutralizing antibodies and a
significant decrease in heterologous antibodies to DENV-2
American genotype were reported in a long-term study in
Cuba [128].This finding may reflect time-dependent changes
in severity of disease observed following secondary dengue
infection.
On the other hand, case fatality rates were observed
to increase month by month during epidemics that were
studied in Cuba. Taking into account that DENV-2 epidemics
occurred in 1981 and 1997,Guzma´n and coworkers proposed a
neutralisation escape mutant hypothesis based on the associ-
ation of severe disease with dengue secondary infection [129].
Furthermore, during the DENV-3 epidemic that occurred in
Havana in 2001, the same sequential increase in case fatality
rates was observed [48, 85, 122].
Although specific viral factors alone probably do not
determine the severity of dengue infection in individual
cases, the demonstrated increasing severity of infection with
time during a single epidemic strongly argues that significant
changes occur in the virus causing the epidemic. Indeed, host
factors do not appear to explain this observation of increasing
severity with time, because it is not logical to assume that the
most susceptible individualswould all be infected towards the
end of the epidemic.
The 1997 Cuban epidemic was the most severe reported
in Cuba to date. Nevertheless, a search for evidence of the
appearance of neutralisation-escape mutants proved nega-
tive. The structural gene sequences were highly conserved
in viruses isolated at different times during the epidemic
[126]. However, nucleotide substitutions were found in the
nonstructural genes and in general they correlated with
the time of sampling, showing a clear pattern of virus
evolution during the epidemic [130]. Therefore, at least in
this study, antibody-driven selection of escape mutants in the
structural genes was not the key selective force. On the other
hand, cytotoxic T-lymphocytes (CTLs) play a crucial role
in controlling infection in RNA viruses, including dengue
viruses [62, 131]. Variation in the epitopes recognized by CTL
is common and frequently offers potential escape routes for
mutant virus. Forthcoming studies will assess whether or not
the reported mutations in NS1 and NS5 proteins [130] are
represented in antibody inducing or CTL epitopes.
Regardless of which mechanism, that is, natural selection
or genetic drift, is operating, it is likely that a fitter virus could
be selected during the period of high transmission in individ-
uals that have experienced secondary infections. However, it
is a very difficult task to study dengue epidemiology because
it is not only endemic in most tropical countries but there are
four serotypes andmany different genotypes often cocirculat-
ing. Nevertheless, Cuba represents a unique epidemiological
setting for this kind of research because epidemics caused by
only one serotype have occurred providing the opportunity
for carefully defined epidemiological studies.
Mutations in the nonstructural genes of DENV-2, iso-
lated during the Santiago de Cuba epidemic, may corre-
late with increased efficiency of virus replication. Variation
in nonstructural proteins has been also associated with
increasing severity in epidemiological settings correspond-
ing to endemic/epidemic transmission [132–136]. However,
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the specific relevance of these types of mutation has not yet
been investigated thoroughly. This is in large part due to the
lack of suitable animal models with which to study dengue
virus “virulence” [51, 137].
During the most recent and severe DENV-4 epidemic
in Puerto Rico in 1998, viruses were distinguished by three
amino acid replacements in the NS2A protein (I14V, V54T,
and P101T), which were fixed more rapidly than would
have been expected by drift alone. This study demonstrates
the significance of viral genetic turnover within a focal
population and the potential importance of adaptive evo-
lution during viral epidemic expansion [132]. In contrast, a
retrospective phylogenetic study of events on the Southern
Pacific islands three decades ago, where severe dengue was
described in patients infected with the DENV-2 American
genotype, recorded attenuation of this virus following a series
of outbreaks involving nonsynonymousmutations, also in the
NS2A gene [138].
Similarly, study of the population structure of dengue
viruses transmitted in Aragua, Venezuela, during the period
2006-2007, under hyperendemic conditions also suggested
that the nonstructural proteins could play an important role
in DENV evolution. According to this particular epidemi-
ological setting, changes in NS1, NS2A, and NS4B proteins
were either favourable or adverse in terms of viral fitness.The
authors argued that specific mutations could be associated
with severe disease but some could be associated with mild
disease due to the appearance of naturally attenuated strains
[139].
The flavivirus NS2A protein is a small, hydrophobic, mul-
tifunctional membrane-associated protein involved in RNA
replication [140, 141], host-antiviral interferon response [142–
145], and assembly/secretion of virus particles [146–148]. In
addition, the NS2A and the NS4B proteins may participate
in the modulation of vector competence [149]. According
to previous reports, changes in NS1 and NS4 proteins could
be involved in viral attenuation [150, 151]. On the contrary,
recent studies have demonstrated that mutations in the NS4B
protein may increase the efficiency of DENV replication. In
addition, it has been suggested that mutations in this protein
may also be involved in species tropism of DENV and may
evenmodulate the balance of efficient replication inmosquito
and mammalian cells [152]. Moreover, it has been shown
that a single amino acid in the nonstructural NS4B protein
namely, L52F, confers virulence on DENV-2 in AG129 mice
through enhancement of viral RNA synthesis [153].
Whilst these results suggest a possible role for the NS
genes in determining viral fitness, the importance of the
structural genes should not be overlooked. The sequences
compared in the cited studies represent a consensus of
those observed within each patient and may not necessarily
represent the dominant variant present in the original clinical
sample. For example, virus isolation usingmosquito cell lines
[154] is known to perturb the distribution of variants in
the original clinical sample. This is particularly important
given that studies of dengue virus populations sampled from
individual humans or mosquitoes have revealed significant
sequence variation [155]. Consequently, a greater focus on
studies of viral population variation during epidemics is
needed and the data should be obtained directly from clinical
samples.
The demonstration of long-term transmission of defec-
tive dengue virus in humans andmosquitoes has added a new
dimension to the study of dengue evolution. The increased
frequency of the “stop-codon” strain was concomitant with
a major reduction in DENV-1 prevalence in Myanmar. The
authors suggested that complementation between defective
variants might provide a mechanism for the survival of
“hyperparasites,” and this process of viral complementation
could impact on pathogen transmission and virulence [156].
Obviously, more comprehensive approaches, including
sequencing of larger numbers of viral genomes obtained
directly fromdiverse clinical samples corresponding to longi-
tudinal studies, are needed to examine how the genetic struc-
ture of dengue virus is influenced by heterotypic antibodies.
Data obtained in two carefully planned clinical studies
of dengue in Nicaragua demonstrate that the complex inter-
play between viral genetics and serotype-specific immunity
determines the risk of severe dengue disease. Indeed, these
data provide insights into viral evolution and the interaction
between viral and immunological determinants of fitness
and virulence. The abrupt increase in disease severity across
several epidemic seasons of DENV-2 transmission coincided
with clade replacement events. Interestingly, DENV-2 strains
corresponding toNI-1 clade caused severe disease specifically
in children who were immune to DENV-1, whereas DENV-
3 immunity was associated with more severe disease among
NI-2B infections, signifying that mutations altering the neu-
tralization profile of someDENV strains can lead to increased
viral fitness [157].
Most dengue virus genomic studies have been directed
at identifying the origin and genetic relatedness of the
viruses causing epidemics. Other studies have focussed on
identifying genetic markers associated with severe disease
and comparing viruses isolated from DF and DHF/DSS
cases within the same epidemiological setting. However,
genetic variations have not been consistently associated with
differences in clinical outcome. Conversely, introduction of
new genotypes/serotypes with replacement/displacement of
the existing viruses or changes in viral populations during
an interepidemic period, extinction events, and sustained
transmission of dengue virus due to repeated introductions
have all been related to changes in the severity pattern of local
epidemics [134, 158–161].
Recently, in Vietnam, the introduction of the Asian 1
genotype of DENV-2 led to the complete replacement of the
resident Asian/American genotype of DENV-2. The trans-
mission fitness advantage of Asian 1 viruses was attributed
to this virus attaining higher viremia levels in humans
[162]. However, there are multiple factors implicated in
the transmission dynamic of DENVs that remain unclear.
Epidemiological data have suggested that fitness is always
context dependent and that as the immunological landscape
changes, viral lineages that evade cross-immunity will be at a
selective advantage [163].
Clearly, there is still wide scope for research on themolec-
ular basis of dengue virus epidemiology and pathogenesis.
We need to know whether or not a circulating dengue virus
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that produces an asymptomatic infection in one host differs
in sequence from the same virus that causes a fatal infection
in another host. We also need to know if different tissues
[164] within a single host house the same dominant dengue
virus strain. Similarly, does the virus that circulates in a
single epidemic have the same sequence in individuals with
different histories of dengue infection?
2.5. Intrahost Genetic Variation. The population genetics
and evolutionary epidemiology of RNA viruses have been
reviewed [165]. The authors describe migration or gene
flow as a factor to consider during RNA virus evolution.
Accordingly, they advocate that migration must not only be
understood at a macroscopic level (i.e., among hosts within
a population, among populations, or between host species),
but also within a single infected individual. From the site
of inoculation, viruses can be transported to several tissues,
generating intrahost spatial variation. This has been studied
in Hepatitis C virus, family Flaviviridae [166]. However, the
effect of a nonhomogeneous population distribution on the
spread, fitness, and variability of virus populations has not
been studied extensively. Nevertheless, a positive correlation
between migration rate and average fitness of the population
has been observed [167]. The outcome of acute Hepatitis C
infection has been attributed to the evolution of viral quasis-
pecies [168]. Large-scale sequencing of complete viral RNA
genomes obtained directly from clinical samples is needed to
investigate the role of variation in viral populations ondengue
pathogenesis. The purifying selection that phylogenies have
revealed [169] thus farmay bemisleading becausemost of the
sequences analysed over the years were obtained from tissue
culture viral isolates. Additionally, an intrinsic inadequacy of
utilising consensus sequences to make inferences concerning
the fitness of viral populations is that consensus sequences
only reflect the majority nucleotide at any given position of
the viral genome. Consequently, low frequency variants will
remain undetected.
Examination of the viral population structure in
mosquitoes and patients has revealed that the sequences of
the major variants are the same but the extent of sequence
variation seen with the mosquitoes is generally lower than
that seen with the patients, suggesting that the mosquito
contributes to the evolutionary conservation of dengue
virus by maintaining a more homogenous viral population
and a dominant variant during transmission [170]. In
addition, by studying the evolutionary relationships of
DENV-1 viruses that have circulated in French Polynesia
and the viral intrahost genetic diversity according to
clinical presentation, Descloux and coworkers suggested
for the first time that clinical outcome may correlate with
intrahost genetic diversity [171]. On the other hand, a recent
study in Vietnam showed no relationship between the
extent and pattern of DENV-1 genetic diversity and disease
severity, immune status, or level of viremia. Interestingly,
despite the high sequence conservation observed, clear
evidence for mixed infection with the presence of multiple
phylogenetically distinct lineages present within the same
host was demonstrated [172].
Indeed, most attempts to investigate intrahost genetic
variation in DENV characterised only a few viral genes or
a limited number of full-length genomes. A new study in
Nicaragua using a whole-genome amplification approach
coupled with deep sequencing to capture intrahost diversity
across the entire coding region ofDENV-2 showed significant
genetic diversity among genes [173]. However, the extension
of that diversity was less than expected, suggesting strong
purifying selection across transmission events as have been
proposed previously [174–176].
Another point of view is that there is no reason to
ignore vector-driven selection [177]. However, the interaction
between virus and vector has been less extensively explored.
By comparing the ability of DENV-1 isolates from Thailand,
spanning a 24-year period, to infect and be transmitted
by St. aegypti, Lambrechts et al. found that a major clade
replacement event in the mid-1990s was associated with a
higher transmission potential of the isolates belonging to
the new clade. Higher transmissibility was mainly due to
a higher infectious titre of virus in the vector’s haemocoel,
which is predicted to result in a higher probability of
transmission.This finding supports the hypothesis thatmajor
clade replacement events can be driven by natural selection
and emphasizes the potentially important role of vector-virus
interactions in DENV evolution [178].
Since the 1900s, the extrinsic incubation period (EIP),
that is the time taken for the viremic bloodmeal to be
amplified in the mosquito and then transmitted to a new
host, had been recognized as an important component of
DENV transmission dynamics. The DENV EIP is generally
considered to be between 8 and 12 days [17]. Nonetheless,
different factors can induce variations in EIP. For example,
considerable degrees of variation in EIP have been shown
to vary depending on the specific DENV strain studied.
Mosquitoes feeding on humans infected with an unadapted
strain of DENV-1 had shorter EIPs (14 days) thanmosquitoes
feeding on humans infectedwith strains at lowmouse passage
levels, where the EIP was 22 days [127]. In addition, long
EIPs have been observedwith dengue virus attenuated strains
[179, 180]. Likewise, highly controlled laboratory studies
have demonstrated the effect of distinct genotypes, serotypes,
and mosquito population on the EIP [181, 182]. Taking into
account the advanced technologies available in molecular
biology, new avenues for the study of virus-vector interac-
tions should reveal newmechanisms involved in dengue virus
transmission dynamics.
3. Disease Control Strategies
Increasing human and associated mosquito population den-
sities and mobility of humans and commercial goods are
the main factors that have determined the very successful
reemergence of DF and DHF during recent decades. In
contrast with YFV, which exploits the same mosquito species
(St. aegypti) to infect humans, the dengue viruses have
evolved to become independent of the need for a reservoir
sylvatic environment with which to sustain their epidemicity.
Thus, in the absence of effective control strategies we are
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faced with the prospect of further increases in morbidity
and mortality due to the dengue viruses. Currently, several
different approaches (reviewed after) are being developed in
the future hope of alleviating this “scourge” of modern times.
3.1. Vector Control. History has shown that vector control
measures can be effective in reducing arthropod-borne virus
diseases [120, 183–186]. However, many developing coun-
tries do not have the necessary resources and infrastruc-
ture for successful eradication measures to be implemented
and sustainable in the manner that has been achieved in
Singapore and Cuba [187]. This situation is exacerbated
by the emergence of resistance to insecticides and the
environmental issues arising from the use of potentially
toxic chemicals [188]. Today, dissemination of insecticide
resistance throughout vector populations is much faster than
the rate of development of new insecticides. In addition,
the existence of cross-resistance, based on the activation of
general detoxifyingmechanisms in the vector, can shorten the
useful lifespan of alternative insecticides or even prevent their
implementation [189].
New approaches to vector eradication including the use
of naturally occurring plant insecticides/larvicides [190] and
vaccines that induce antibodies to impair vital functions in
mosquitoes [191] are being considered but such approaches
are unlikely to provide effective vector control measures in
the near future.
Primary prevention of dengue is largely dependent on
larval and adult mosquito control. St. aegypti surveillance
has relied heavily upon larval indices. However, this has
been strongly criticised as they provide little information
to determine the risk of DENV transmission. The studies
of Bisset Lazcano and colleagues used pupal surveillance
for the St. aegypti control programme in Cuba and focused
on the most productive mosquito water containers [192].
In urban areas, St. aegypti breed on water that collects in
artificial containers such as plastic cups, used tyres, broken
bottles, flowerpots, and other water traps. Elimination of
these containers is the most effective way of reducing the
mosquito breeding grounds. The use of insect repellents,
mosquito traps, and mosquito nets in the home can also be
moderately effective in reducing the number of bites due to
mosquitoes.
Novel alternative approaches have also been investigated.
InVietnam, trials were conducted inwhich children and local
communities were encouraged to place, a known mosquito
predator, the crustacean Mesocyclops [193], in water tanks
and discarded containers where St. aegypti are known to
thrive [194]. The concept exploited the principle that this
procedure might be more cost-effective and environmentally
friendly than the use of pesticides. Over a period of years
and in defined rural provinces of Viet Nam a reduction
in mosquitoes and dengue fever was observed [195, 196].
However, such approaches are only likely to be successful
in regions of countries with the organisational infrastruc-
ture and appropriate community attitudes. A community
education strategy is utilised to promote participation in
dengue prevention in Cuba, resulting in reduced mosquito
vector infestation levels. The main principle has been to
increase community participation in decision-making and
strengthening the competence of the medical teams and
community working groups [197]. Whether or not a similar
approach could be successfully applied to major cities and
urban areas in other countries remains to be seen.
An alternative approach involves infecting St. aegyptiwith
the bacteriumWolbachia [189]. Early studies suggest that this
reduces the adult lifespan of the mosquito by 50% [198]. This
is important because the adult femalemosquito is the primary
vector of the virus. Insects infected by Wolbachia transmit
them transovarially to the next generation.Thus, by reducing
the lifespan of the mosquito, virus-vector competence, and
virus transmission efficiency, a significant reduction of St.
aegypti should be observed. Another important feature of
Wolbachia is its ability to induce resistance to a variety of
pathogens, including DENV, in its insect hosts [199]. In
the transinfected St. aegypti, all the three different types of
Wolbachia, wAlbB, wMelPop-CLA, and wMel, induce sig-
nificant inhibition of DENV replication and dissemination,
resulting in either complete or partial block of virus trans-
mission [200–202]. Recent studies also show that Wolbachia
induces production of reactive-oxygen species which then
activate the Toll-pathway to induce expression of antiviral
effectors [203]. Interestingly, it was recently demonstrated
that nativeWolbachia symbionts limit transmission of DENV
in St. albopictus by restricting the delivery of infectious viral
particles from the mosquito saliva when biting. These results
might therefore explain the low vector competence of St.
albopictus for dengue and thus its relativelyweak contribution
as an epidemic dengue vector [204].
Understanding how Wolbachia density is regulated by
mosquito hosts and how the Wolbachia machinery controls
its replication will facilitate the current effort to eliminate
dengue through Wolbachia-based population replacement
[205].
The genetic structure of St. aegypti populations and its
implications for potential mosquito releases have been stud-
ied in Queensland, Australia [206], and Tri Nguyen village,
Vietnam [207, 208]. Populations of St. aegypti artificially
infected with strains of Wolbachia pipientis that
interfere with its vector competence are being backcrossed
into wild mosquito genetic backgrounds from north
Queensland and assessed as potential candidates for release
[209]. In addition, a pilot release—http://www.eliminateden
gue.com/project/vietnem/progress —of infected mosquitoes
has been authorised to take place from April 2013 on Tri
Nguyen village (611 households) on Hon Mieu Island in
central Vietnam. Subject to satisfactory results larger scale
studies could be launched within five years [210].
Promisingly, studies related with the effect of Wol-
bachia on insecticide susceptibility in lines of St. aegypti
have demonstrated that spreading Wolbachia infections are
unlikely to affect the efficacy of traditional chemical methods
of controlling mosquito outbreaks [211].
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3.2. Development of Vaccines against Dengue Viruses. It is
generally agreed that vaccination can provide an effective
method with which to control virus diseases. In the case of
the dengue viruses, the four serotypes are sufficiently anti-
genically different that it is considered necessary to produce
four monovalent vaccines, which will then be mixed to pro-
duce a tetravalent immunological response. This is a logical
approach that has previously been employed successfully
with the three monovalent poliovirus vaccines. However, as
discussed earlier, the dengue viruses also present the problem
of antibody mediated enhancement of disease severity [75,
118, 212]. Long-term protection is essential as severe dengue
has been observed in individuals secondarily infected more
than 20 years after the primary infection [63, 85]. As it is
virtually impossible to test whether or not the tetravalent
formula would overcome this potential problem, an element
of uncertaintymight prevail following the introduction of the
vaccines in Asia and/or Latin America where dengue viruses
are most prevalent. In addition, although the protective
role of neutralizing antibodies is recognised, correlates of
protection need to be defined [213].
Several different approaches are being employed to
develop dengue virus vaccines. The vaccine pipeline includes
live empirically attenuated vaccines, newer live attenuated
vaccines developed using infectious clone technology, genetic
vaccines using virus and plasmid vectors, and many recom-
binant subunit vaccine candidates [214].
Potential vaccines already progressing through clinical
trials include a live attenuated tetravalent vaccine, produced
via serial subculture in primary dog kidney cells [215–217].
Another approach involves the use of genetic modification
of dengue viruses to attenuate their virulence [218–222].
Although vaccine candidates based on infectious virus have
shown the greatest progress amongst different dengue vaccine
approaches, there are safety concerns associated with their
use based on potential reactogenicity, interference amongst
the viruses, possible reversion to native virus, and possible
increase of virus infectivity and/or virulence via antibody
dependent enhancement [223].
An alternative approach is based on the use of the live
attenuated YFV 17D vaccine as a backbone for the production
of four chimaeric live attenuated viruses in which the prM
andE genes of the 17D vaccine virus are replaced by the corre-
sponding genes of the four dengue virus serotypes [224–226].
Preclinical studies demonstrated that the tetravalent vaccine
is genetically and phenotypically stable, nonhepatotropic, less
neurovirulent than the tried and tested YFV 17D vaccine,
and does not infect mosquitoes by the oral route. Vaccine
reactogenicity, viremia induction, and antibody responses
have been investigated in phase 1 trials in the USA, the
Philippines, andMexico. Preclinical and clinical trials showed
favourable immunogenicity and short-term safety of this
vaccine [227]. Relatively favourable results of phase 2 trials
were published recently. A surprising lack of efficacy against
DENV2 was observed, and the fact that DENV2 was the
prevalent serotype during the study diminished the overall
vaccine efficacy in this setting [228].
Several possible causes of this apparent failure have been
proposed including significant genetic differences between
the circulatingDENV-2 genotype and the strain incorporated
in the yellow fever chimaeric vaccine, imbalanced viraemias,
or immune responses due to interference. Nevertheless,
Sanofi’s CYD dengue vaccine has been discussed as a poten-
tial “75% solution” referring to the vaccine’s efficacy towards
three of the four DENVs in the context of potential antibody-
dependent enhancement. The general view seems to be that
this approach would be inappropriate [229]. Probably, the
most relevant issue is related to the long-term safety of such
vaccines. DENV-2 has been associated with severe disease
in several epidemiological settings. In fact, studies in Cuba
demonstrated that disease severity increased notably when
infection with DENV-2 follows infection with DENV-1 at
an interval of 20 years [64], probably due to a significant
decrease inmean titre of heterologous neutralizing antibodies
[128]. Thus, there is justified concern that CYD vaccinated
individuals could develop severe disease if infection with
DENV-2 occurs after a relatively long interval of time.
On the other hand, depending on the DENV-2 genotype
that might subsequently circulate, it cannot be ruled out
that heterologous neutralisation might lead to a satisfactory
immune outcome, as occurred in Cuba during the 2001-
2002 epidemic caused by DENV-3, where most DENV-2
immune individuals (infected in 1981) developed asymp-
tomatic DENV-3 infections whilst a high proportion of the
DENV-1 immune cases suffered overt disease [63, 230].
In summary our limited understanding of the underlying
processes of the immunopathological response to primary
and successive infections with the four DENV largely deter-
mines our inability to predict the clinical outcome [231, 232].
Nevertheless, ongoing large-scale phase 3 studies in more
than 30,000 volunteers in ten countries in Latin America and
Asia should provide critical data with which to overcome
initial problems identified with the CYD dengue vaccine
candidate.
A similar approach is being developed based on the
attenuated DENV-2 virus, DENV-2 PDK-53, and three chi-
maeric viruses containing the prM and E genes of DENV-
1, DENV-3, and DENV-4 virus in the genetic backbone of
the DENV-2 PDK-53 virus (termed DENVax). Based on the
safety, immunogenicity, and efficacy in preclinical studies in
animalmodels, phase 1 clinical testing of tetravalent DENVax
has been initiated [233–235]. This candidate might have
advantages as the DENV backbone could reduce the risk of
unanticipated effects due to the YFV NS proteins present in
the Sanofi vaccine candidate [228].
Potential vaccines not yet progressing through clinical
trials include the development of subunit vaccines based on
domain III of the dengue virus envelope protein. Recom-
binant fusion proteins formed by domain III and P64k
protein from Neisseria meningitides expressed in E. coli
induce functional and protective immunity in mice and
nonhuman primate models inducing highly serotype specific
immune responses [236–238]. Additionally, the domains
of each serotype have been engineered in tandem in a
yeast expression system [239]. A recombinant adenovirus
system has been utilised to express the DENV NS1 proteins
[240]. The paediatric measles vaccine has been modified to
express a fragment of the DENV-1M protein together with
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domain III of the envelope protein [241]. More recently, the
evaluation in mice of a novel domain III-capsid chimaeric
protein expressed in E. coli provides additional evidence
for a crucial role of cell-mediated immunity in protection
against dengue virus [242–245]. Finally, a novel single-dose
lipidated consensus dengue virus envelope protein domain
III (LcEDIII) subunit vaccine was shown to induce humoral
and cellular immune responses in mice [246]. This group
also evaluated the efficacy of the newly developed water-in-
oil-in-water multiphase emulsion system, termed PELC plus
CpG oligodeoxynucleotides, in potentiating the protective
capacity of dengue-1 envelope protein domain III concluding
that it could be a promising adjuvant for recombinant protein
candidates [247].
Whilst subunit vaccines may have some advantages in
terms of type-specific neutralisation with a low potential for
inducing ADE via cross-reactive antibodies and low reacto-
genicity, multiple doses are usually needed to ensure long-
term immune protection. However, it has been suggested that
recombinant domain III vaccine could function as a booster
if used in combination with live vaccine [223].
It is anticipated that within the next five years, increased
understanding of the basis for dengue pathogenesis [248] and
the protective immune response to DENV will improve our
ability to develop safer and more effective vaccines [223].
Critical issues in dengue vaccine development have been
reviewed [249]. Of relevance is the potential impact of
vaccination on the evolution of naturally occurring DENVs.
Vaccination could ultimately produce an environment where
relatively low transmission of natural DENV occurs. This is
especially relevant if vaccination is focused on a selected por-
tion of the population, thereby increasing stochastic events
that will allow new DENV genotypes to emerge possibly
with greater virulence. Furthermore, dengue vaccinationmay
produce a background of low titres of enhancing antibody
to specific DENV serotypes, resulting in the emergence of
specific serotypes in a population. Recent studies suggest
that strain diversity may limit the efficacy of monoclonal
antibody therapy or tetravalent vaccines against DENV as
neutralization potency generally correlates with a narrowed
genotype specificity [250]. Consequently, a better under-
standing of dengue immunopathogenesis will assist not only
development of therapeutic interventions but also the under-
standing of dengue vaccine efficacy or vaccine adverse events
[97]. Therefore, laboratory surveillance of dengue needs to
be improved considerably to increase our knowledge of the
circulating viruses at the molecular level, preferably before
the introduction of a vaccine on a large-scale.
3.3. Development of Antivirals againstDengueViruses. Whilst
no approved antiviral therapeutic agents are available to
treat individuals presenting with symptoms of DF/DHF,
several potential virus inhibitors are under consideration for
further development. The dengue viruses provide a variety
of potential targets for inhibitors of infection/replication. As
Hepatitis C virus (HCV) is also a member of the Flaviviridae,
antivirals under development to control disease due to HCV
may also prove to be effective against the dengue viruses.
One of the major problems likely to be encountered is drug
resistance. Consequently, the discovery and development of
at least two antivirals that attack different viral targets should
be aminimumgoal. Anothermajor hurdle for dengue viruses
is the lack of availability of a validated animal model that
faithfully reflects DHF and DSS observed in patients.
The NS5 viral RNA dependent RNA polymerase (RdRp)
and the methyl transferase, as well as the NS3 protease and
helicase, are considered good targets for inhibitors of dengue
infection, because they are all major components of the
replicative viral complex [251].The viral envelope (E) protein
is also a good target for antivirals. The use of E protein-
specific monoclonal antibodies has been shown to have some
potential in this context [252]. The NS1, prM, and capsid
protein of the dengue viruses have not been studied at the
same level of intensity, and thus there are few if any potential
antivirals against these targets.
One approach that appears quite successful both in vitro
and in vivo has been the demonstration that specific antisense
morpholino oligomers can inhibit dengue virus replication
[253, 254]. However, major efforts are required to reduce
the risk of toxicity and to provide safe and effective delivery
systems for these oligomers [252, 255].
Other approaches are being utilised to identify fla-
vivirus chemotherapeutic agents, including screening known
inhibitors of other viruses, rational design based on pro-
tein crystal structures or secondary viral RNA structures,
optimization of known viral inhibitors, use of humanized
antibodies, use of immunoglobulins, and nucleic acid-based
therapy [256].
Polyoxotungstates and sulphated polysaccharides show
some potential as viral inhibitors. They impair flavivirus
adsorption and entry into host cells in vitro, apparently
by binding to the cell surface [257, 258]. Sulphated galac-
tomannans protected mice from lethal YFV infection when
inoculated simultaneously with the virus [259].
The licensed drug Ribavirin has been used to treat a
number of RNA viral infections. It functions as an RNA
cap analogue and mutagen, causing errors in synthetic
pathways [260–262]. However, the in vitro and in vivo
activity of Ribavirin against YFV and DENV was poor [263–
265]. Prophylactic Ribavirin treatment of rhesus monkeys
infected with DENV had little effect on viremia [266] and
in mice, intraperitoneal administration of Ribavirin had no
effect on survival following intracerebral inoculation with
DENV.However, treatment with Ribavirin-2󸀠,3󸀠,5󸀠-triacetate,
a prodrug of Ribavirin, resulted in a significantly increased
survival time and rate, possibly due to its higher ability to
cross the blood-brain barrier [267].
Nucleoside analogues, characterized for chemotherapeu-
tic use against HIV and Hepatitis B virus, show inhibitory
activity in cell culture against YFV, DENV, and West Nile
virus (WNV) [268]. Rather than blocking RNA replication,
some analogues inhibit flaviviruses by inhibiting nucleo-
side triphosphate synthesis in host cells. For example, 6-
azauridine acetate, pyrazofurin, and 2 thio-azauridine inhibit
orotidine monophosphate decarboxylase (OMPDC). In con-
trast, mycophenolic acid and Ribavirin-2󸀠,3󸀠,5󸀠-triacetate
inhibit inosine monophosphate dehydrogenase (IMPDH)
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and block viral RNA synthesis [269, 270]. Carbamate pro-
drugs have also been recommended as IMPDH inhibitors
since they show in vivo activity [271]. Recently a uracil-
based multifunctional compound was shown to have strong
activity against dengue virus. It is likely that the mechanism
of action of the antiviral activity of this compound is through
inhibition of the enzyme, IMPDH [272].
An alternative strategy in the search for effective antivirals
that potentially reduces the lead-time for their development
is to identify drugs already licensed for use to control diseases
other than those caused by the target virus. For example,
the aminoglycoside, Geneticin (G418), was recently shown
to have antiviral activity against bovine viral diarrhea virus
(BVDV). Since BVDV,DENV, andYFV all belong to the virus
family Flaviviridae, it seems possible that a common step
in their life cycle might be affected by this aminoglycoside.
Geneticin prevented the cytopathic effect resulting from
DENV-2 infection of BHK cells, in a dose-dependentmanner
[273]. However, Geneticin had no detectable effect on YFV in
BHK cells.
Ivermectin, a broadly used antihelmintic drug, displays
specific inhibitory unwinding activity against helicases from
several flaviviruses, including YFV, DENV, and WNV with
the half maximal inhibitory concentration (IC
50
) values in
the submicromolar range [274]. Preliminary studies indicate
higher binding efficiency with YFV than with DENV. Never-
theless, disappointingly, Ivermectin did not protect hamsters
against infection with YFV. Structure-based optimization
may result in analogues exerting potent activity against
flaviviruses both in vitro and in vivo.
Doxorubicin is an antineoplastic antibiotic obtained
from Streptomyces peucetius. This antibiotic exhibits in vitro
antiviral activity against the YFV17D vaccine strain and the
DENV-2 NGC strain. Doxorubicin proved to be cytotoxic
in uninfected host cells. However, a novel derivative of
doxorubicin, SA-17, showed excellent antiviral activity against
DENV andmarkedly reduced cytopathogenicity [275]. Dose-
dependent anti-DENVactivity was confirmed using a dengue
reporter virus. Time-of-drug addition studies indicated that
SA-17 acts at an early stage of the replication cycle. It does not
inhibit the replication of the replicon and thus does not work
at the level of the viral replication machinery. Further studies
revealed that SA-17 exerts it activity via a virucidal effect, even
when using very high titres of the virus as the inoculum.
A large number of small molecules derived by computer
modelling of known enzyme domains were screened for
inhibitory activity against DENV-2 virus. Two of these
molecules, ARDP0006 and ARDP0009, inhibited DENV-2
with high efficiency. ARDP0009 had no apparent toxicity
at the concentrations tested. Selectivity indices calculated
for ARDP0006 and ARDP0009 were comparable to those
calculated for Ribavirinwhich has demonstrated inhibition of
the DENV-2-O-methyltransferase NS5 [276] and HCV repli-
cation when used in combination with interferon. Antiviral
activity, in vitro, of 3󸀠,5󸀠 di-O-trityluridine has also been iden-
tified. The compound inhibits DENV and YFV replication
by targeting the elongation process of the viral NS5 RNA-
dependent RNA polymerase. A nucleoside analogue (T-705)
which is a substituted pyrazine compound that has been used
in clinical trials for the treatment of human influenza virus
infection is an analogue of T-1106, a knownHCV polymerase
inhibitor [277]. T-705 significantly improved survival and
disease parameters in YFV-infected hamsters despite the lack
of good in vitro antiviral activity. These studies highlight
the possibility that nucleoside analogues could potentially
be developed for flavivirus therapy although more potent
compounds with reduced toxic effects on the host cells will
need to be generated.
Flaviviral inhibitory activity has also been observed with
plant extracts. Boesenbergia rotunda (L.) Mansf. Kulturpfl.
(BR) is a common spice belonging to a member of the ginger
family (Zingiberaceae). Some of the BR compounds, such
as flavanoids and chalcones, have been shown to be phar-
maceutically active.The chalcone, cardamonin, isolated from
BR, was recently reported to exhibit appreciable anti-HIV-1
protease inhibition [278]. Moreover, inhibitory activity by six
compounds isolated from BR has also been demonstrated on
DENV-2 virus NS3 protease activity.
In conclusion, whilst mosquito control strategies have
been shown to be successful in reducing the incidence
of dengue infections, such methods are most effective in
those tropical/subtropical countries that have well-developed
human and environmental health infrastructures. Clearly,
there is a real need for more effort to understand the
complex epidemiology and pathogenesis of the dengue
viruses to expedite the development of suitable vaccines
and/or antiviral therapies. Although some vaccine candidates
appear promising, as yet none has been licensed. Due to the
presence of the four DENV serotypes, these viruses present
a different situation from YFV, tick-borne encephalitis virus,
and Japanese encephalitis virus. The question of whether or
not deteriorating antibody levels will leave vaccinated people
liable to the development of DHF via ADE will need to be
addressed. Moreover, the relationships between the presence
of neutralizing antibodies, the level of protection afforded
and the duration of protection by each of the four serotypes
will need to be critically assessed. There is a pressing need
for global collective efforts to develop antiviral therapeutics
with which to combat dengue viruses. The current trend
of expanding our efforts on antiviral drug discovery is
encouraging in this respect.
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